NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Thursday that its first-quarter revenues increased 26 percent with strong growth for both its instruments and consumables.

The South San Francisco, Calif.-based firm had total revenues of $10.9 million for the three months ended March 31, compared to $8.7 million for the first quarter of 2011. It beat Wall Street's estimate for revenues of $10.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."